Dr. Brody on Managing CAR T-Cell Therapy Toxicities in MCL

Video

Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.

Joshua Brody, MD, director of the Lymphoma program at Icahn School of Medicine, Mount Sinai Hospital, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma (MCL).

Cytokine release syndrome (CRS) and neurotoxicity are adverse effects associated with CAR T-cell therapy that can be managed through conservative therapy, observation, fluid hydration, and pressor drugs, Brody explains. Patients with severe CRS can receive steroids and tocilizumab (Actemra), an interleukin (IL)-6 receptor antibody. Novel therapies, such as the IL-1 receptor antagonist anakinra (Kineret), have also demonstrated efficacy in this setting.

Patients who develop neurotoxicity are treated with a similar strategy, says Brody, though he notes that the management protocol for CRS is further along than that of neurotoxicity.

Managing the risk of CRS and neurotoxicity before a patient begins treatment with CAR T-cell therapy is important, says Brody. Moreover, moving CAR T-cell therapy earlier in treatment to the third-line setting could be another option, as tumor bulk plays a key role in toxicity development. Debulking patients with effective therapies prior to CAR T-cell therapy may be key to utilizing the modalities earlier, concludes Brody.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.